OBJECTIVES: Neutral endopeptidase modulates the growth of lung cancer, while aminopeptidase N degrades the extracellular matrix and is involved in cell motility. We studied the metastasis mechanism to detect novel metastasis-associated molecules and to evaluate them for clinical application. METHODS: We studied the relationship between the expression of neutral endopeptidase and aminopeptidase N by quantitative reverse transcript-polymerase chain reaction analysis in 132 patients with non-small cell lung cancer undergoing radical surgery from 1991 to 1996. RESULTS: Patients with neutral endopeptidase-positive and aminopeptidase N-negative tumors were defined as group A, those with neutral endopeptidase-positive and aminopeptidase N-positive or neutral endopeptidase-negative and aminopeptidase N-negative tumors as group B, and those with neutral endopeptidase-negative and aminopeptidase N-positive tumors as group C. The 5-year survival of group A patients (92.9%) was significantly better than that of group B patients (64.7%) and much better than that of group C patients (38.2%) (P = 0.0011). Neutral endopeptidase and aminopeptidase N thus have statistically significant P in overall survival in Cox regression (P = 0.019). CONCLUSION: Neutral endopeptidase and aminopeptidase N gene expressions are significant indicators of prognosis.
OBJECTIVES: Neutral endopeptidase modulates the growth of lung cancer, while aminopeptidase N degrades the extracellular matrix and is involved in cell motility. We studied the metastasis mechanism to detect novel metastasis-associated molecules and to evaluate them for clinical application. METHODS: We studied the relationship between the expression of neutral endopeptidase and aminopeptidase N by quantitative reverse transcript-polymerase chain reaction analysis in 132 patients with non-small cell lung cancer undergoing radical surgery from 1991 to 1996. RESULTS:Patients with neutral endopeptidase-positive and aminopeptidase N-negative tumors were defined as group A, those with neutral endopeptidase-positive and aminopeptidase N-positive or neutral endopeptidase-negative and aminopeptidase N-negative tumors as group B, and those with neutral endopeptidase-negative and aminopeptidase N-positive tumors as group C. The 5-year survival of group A patients (92.9%) was significantly better than that of group B patients (64.7%) and much better than that of group C patients (38.2%) (P = 0.0011). Neutral endopeptidase and aminopeptidase N thus have statistically significant P in overall survival in Cox regression (P = 0.019). CONCLUSION: Neutral endopeptidase and aminopeptidase N gene expressions are significant indicators of prognosis.
Authors: M A Shipp; G E Tarr; C Y Chen; S N Switzer; L B Hersh; H Stein; M E Sunday; E L Reinherz Journal: Proc Natl Acad Sci U S A Date: 1991-12-01 Impact factor: 11.205
Authors: M A Shipp; N E Richardson; P H Sayre; N R Brown; E L Masteller; L K Clayton; J Ritz; E L Reinherz Journal: Proc Natl Acad Sci U S A Date: 1988-07 Impact factor: 11.205
Authors: R Pasqualini; E Koivunen; R Kain; J Lahdenranta; M Sakamoto; A Stryhn; R A Ashmun; L H Shapiro; W Arap; E Ruoslahti Journal: Cancer Res Date: 2000-02-01 Impact factor: 12.701
Authors: A J Cohen; P A Bunn; W Franklin; C Magill-Solc; C Hartmann; B Helfrich; L Gilman; J Folkvord; K Helm; Y E Miller Journal: Cancer Res Date: 1996-02-15 Impact factor: 12.701
Authors: Kyuichi Kadota; Daniel Buitrago; Ming-Ching Lee; Jonathan Villena-Vargas; Camelia S Sima; David R Jones; William D Travis; Prasad S Adusumilli Journal: Lung Cancer Date: 2015-06-15 Impact factor: 5.705
Authors: Kristina Viktorsson; Carl-Henrik Shah; Therese Juntti; Petra Hååg; Katarzyna Zielinska-Chomej; Adam Sierakowiak; Karin Holmsten; Jessica Tu; Jack Spira; Lena Kanter; Rolf Lewensohn; Anders Ullén Journal: Mol Oncol Date: 2016-01-02 Impact factor: 6.603
Authors: Katharina Leithner; Christoph Wohlkoenig; Elvira Stacher; Jörg Lindenmann; Nicole A Hofmann; Birgit Gallé; Christian Guelly; Franz Quehenberger; Philipp Stiegler; Freyja-Maria Smolle-Jüttner; Sjaak Philipsen; Helmut H Popper; Andelko Hrzenjak; Andrea Olschewski; Horst Olschewski Journal: BMC Cancer Date: 2014-01-25 Impact factor: 4.430